Shifa International Hospitals (KAR:SHFA) Research & Development: ₨0 Mil (TTM As of Mar. 2026)


KAR:SHFA Shifa International Hospitals Ltd KAR:SHFA
85 GF Score
Price ₨520.98
GF Value ₨453.79
Valuation Modestly Overvalued
View Full Analysis

What is Shifa International Hospitals Research & Development?

Shifa International Hospitals KAR:SHFA 85 Research & Development is ₨0 Mil as of Mar. 2026. GuruFocus rates KAR:SHFA with a GF Score™ of 85/100 and a GF Value™ of ₨453.79 (Modestly Overvalued).

Research & Development is the aggregate amount of research and development expenses during the year. Shifa International Hospitals's Research & Development for the three months ended in Mar. 2026 was ₨0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₨0 Mil.

Shifa International Hospitals  (KAR:SHFA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Shifa International Hospitals Research & Development Related Terms

Shifa International Hospitals Research & Development Historical Data

* Premium members only.

The historical data trend for Shifa International Hospitals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shifa International Hospitals Research & Development Chart

Shifa International Hospitals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Shifa International Hospitals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KAR:SHFA
85GF Score
Shifa International Hospitals Ltd KAR:SHFA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shifa International Hospitals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₨0 Mil mean?
Shifa International Hospitals (KAR:SHFA) has a Research & Development of ₨0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Shifa International Hospitals and its competitors.
Is Shifa International Hospitals' Research & Development too high?
Shifa International Hospitals' current Research & Development is ₨0 Mil. Overall, Shifa International Hospitals has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shifa International Hospitals' Research & Development compare to HCA and THC?
Shifa International Hospitals' Research & Development of ₨0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Shifa International Hospitals and its competitors. Shifa International Hospitals's current Research & Development is ₨0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shifa International Hospitals stock overvalued right now?
Based on GuruFocus' analysis, Shifa International Hospitals (KAR:SHFA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨453.79, compared to a current price of ₨520.98 — trading 14.8% above its estimated fair value. The current Research & Development is ₨0 Mil. Shifa International Hospitals' overall GF Score™ is 85/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Shifa International Hospitals (KAR:SHFA), the current Research & Development is ₨0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shifa International Hospitals (KAR:SHFA) Overvalued in 2026?

Based on GuruFocus' analysis, Shifa International Hospitals stock appears to be overvalued. The current stock price of ₨520.98 is trading 14.8% above its estimated GF Value™ of ₨453.79. GuruFocus considers Shifa International Hospitals to be Modestly Overvalued.

Key valuation signals for KAR:SHFA:

  • Research & Development: ₨0 Mil
  • GF Value™: ₨453.79 vs. price of ₨520.98 (14.8% above fair value)
  • GF Score™: 85/100

No single metric tells the full story. See the KAR:SHFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shifa International Hospitals Business Description

Address Pitras Bukhari Road, Sector H-8/4, Islamabad, PAK
Shifa International Hospitals Ltd operates a network of medical centers and hospitals in Pakistan, providing a wide range of medical and surgical services across various specialties. The company offers organ transplant services, including liver, kidney, bone marrow, and corneal transplants. It generates revenue through patient care services, diagnostics, pharmacy operations, and support services such as emergency care and outpatient clinics. Shifa also operates lab collection points, day care surgeries, and diagnostic centers. The company has a presence in multiple cities through hospitals, medical centers, and subsidiaries that support healthcare services and infrastructure development.
85GF Score

Get the complete analysis for KAR:SHFA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨520.98
Price
₨453.79
GF Value